News & Events News

May 22, 2013 - Auxogyn Selected to Present at European BioEquity Conference in Stockholm

“Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, announced that Lissa Goldenstein, CEO and President of Auxogyn will be a featured speaker at the 14th European BioEquity Conference being held today in Stockholm, Sweden..." more >>

May 15, 2013 - Auxogyn Honored as a Finalist in the Red Herring 2013 Top 100 North America Award

“Auxogyn, Inc. announced today that it has been selected as a finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region..." more >>

May 7, 2013 - Auxogyn Announces Availability of Groundbreaking IVF Test, Eeva™, at Bourn Hall Clinic; Designed to Improve Outcomes

“The cutting-edge, new Early Embryo Viability Assessment™ (Eeva) Test designed to improve in vitro fertilization (IVF) outcomes is now available to couples seeking IVF treatment in East England. Using intelligent computer vision software to analyze key scientifically and clinically validated cell-division parameters, the Eeva Test is the first and only non-invasive IVF test..." more >>

February 28, 2013 - Auxogyn Appoints Women's Health Leader, Kathryn A. Tunstall, To Board of Directors

“Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the appointment of Kathryn A. Tunstall to the company's Board of Directors..." more >>

January 24, 2013 - Auxogyn Announces European Expansion of New Non-Invasive Early Embryo Viability Assessment (EEVA™) Test With Availability at First Clinic in Ireland

“Auxogyn Inc. today announced that Sims IVF is the first fertility clinic in Ireland to offer patients the Early Embryo Viability Assessment (Eeva) Test..." more >>

January 3, 2013 - Auxogyn Announces First European Patent for EEVA™ Test

“We are thrilled with the European Patent Office’s decision to issue this patent,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “This European patent provides further validation that bodies governing intellectual property worldwide recognize the inventive work done at Stanford University in the field of human embryology..." more >>

December 27, 2012 – Fertility Road: Embryo Monitoring Designed to Improve IVF Outcomes 

"Revolutionary new non-invasive test that uses intelligent imaging software to measure and predict with more accuracy which embryos will likely grow to the blastocyst stage..." more>>

December 4, 2012 – Auxogyn Announces Publication of New Data Key to Identifying Which Developing Human Embryos are Most Likely to Result in Successful IVF Pregnancy

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced new data key to identifying which developing human embryos are the most likely to result in successful pregnancies during in vitro fertilization (IVF) procedures. more»

December 4, 2012 – Auxogyn Announces IVF Research Using its EEVA Test Awarded Top Honor at Fertility Society of Australia Scientific Meeting

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that research involving the use of the company’s flagship product, the Early Embryo Viability Assessment (Eeva) Test, was recognized by the Fertility Society of Australia at its 2012 Scientific Meeting with the Ferring “Best Scientific Paper Award.” more»

October 22, 2012 – Auxogyn Presents New Data Validating Eeva's Ability to Predict Blastocyst Development in IVF By Day 3 With High Specificity and Consistency

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced two presentations describing new data from a prospective, cohort study conducted at multiple independent centers. more»

October 18, 2012 – Merck Serono and Auxogyn Announce Collaboration on EEVA™ Test

Merck Serono, a division of Merck, Darmstadt, Germany, and Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that they have entered into a strategic agreement focused on Auxogyn’s proprietary Early Embryo Viability Assessment (Eeva) Test. more»

October 11, 2012 – Auxogyn Strengthens Intellectual Property Rights for EEVA™ Test

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the U.S. District Court for the Northern District of California has ruled in favor of Auxogyn and Stanford University and dismissed a patent lawsuit initiated by Unisense Fertilitech. more»

September 17, 2012 – Auxogyn and Hewitt Fertility Center Announce First Availability of New Non-Invasive Early Embryo Viability Assessment (EEVA) Test in the European Union

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the launch of its Early Embryo Viability Assessment (Eeva) Test in the European Union (EU), with the first installation at the Hewitt Fertility Centre in Liverpool. more»

July 23, 2012 – Auxogyn Receives CE Mark for Non-Invasive Early Embryo Viability Assessment (EEVA) Test

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that it has received CE mark approval to market its flagship product, the Early Embryo Viability Assessment (Eeva) Test, which is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. more»

July 2, 2012 – Auxogyn Presents New Data Showing the Ability of EEVA™ to Non-Invasively Predict Embryo Advancement With Increased Accuracy

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today presented data showing the ability of its flagship product, the Early Embryo Viability Assessment (Eeva) Test, to predict embryo advancement with a new level of accuracy. The Eeva™ Test uses intelligent computer vision software to measure key parameters from video images and predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage. more»

June 19, 2012 – Auxogyn and Reproductive Medicine Associates of New Jersey Partner to Advance In Vitro Fertilization Research

Auxogyn, Inc., a company at the forefront of reproductive health innovation, today announced the commencement of a groundbreaking research study with Reproductive Medicine Associates of New Jersey (RMANJ), an internationally-renowned fertility clinic that has pioneered and successfully implemented cutting-edge clinical advancements to more accurately detect healthy embryos for patients undergoing in vitro fertilization (IVF). more»

June 5, 2012 – Auxogyn Raises $18 Million in Series B Funding

Auxogyn, Inc., a privately-held company advancing women’s reproductive health, today announced it raised $18 million through a Series B financing. The proceeds will be used to support regulatory clearance and commercial launch of Auxogyn's Early Embryo Viability Assessment, Eeva, a non-invasive test designed to provide objective information regarding the viability of embryos during in vitro fertilization (IVF) procedures. more»

February 9, 2012 – Auxogyn Takes Top Honor As “Most Promising Company” at Personalized Medicine World Conference 2012

Auxogyn, Inc., a privately-held company advancing women’s reproductive health, announced today that the Personalized Medicine World Conference (PMWC) and Prescience International selected the Auxogyn as the ‘Most Promising Company’ at PMWC2012 annual conference, held January 23-24, 2012. more»

February 2, 2012 – Auxogyn Announces the Close of the Final Tranche of its Series A Financing, Bringing the Total Funding to $20 Million.

Auxogyn, Inc., a privately-held company focused on advancing women’s reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures. more»

June 27, 2011 - Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization

Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that the U.S. Patent and Trademark Office (USPTO) issued patent number 7,963,906 covering three predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn’s early embryo viability assessment (Eeva™) System.... more»

July 4, 2011 – Auxogyn Announces Initiation of Clinical Study for Non-Invasive Embryo Assessment Technology Used During In Vitro Fertilization

Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that it initiated a multi-center clinical study to validate its early embryo viability assessment (Eeva™) System for use in in vitro fertilization (IVF). more»

October 4, 2010 - Auxogyn Licenses Non-Invasive Embryo Assessment Technology from Stanford University

Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures... more»